Cwm LLC Buys 28,387 Shares of Nuvation Bio Inc. $NUVB

Cwm LLC increased its position in Nuvation Bio Inc. (NYSE:NUVB) by 296.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,963 shares of the company’s stock after acquiring an additional 28,387 shares during the quarter. Cwm LLC’s holdings in Nuvation Bio were worth $74,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC bought a new position in shares of Nuvation Bio in the second quarter worth approximately $25,000. Kingswood Wealth Advisors LLC bought a new position in Nuvation Bio in the 2nd quarter worth $42,000. Rafferty Asset Management LLC boosted its holdings in Nuvation Bio by 30.1% in the 1st quarter. Rafferty Asset Management LLC now owns 31,652 shares of the company’s stock worth $56,000 after buying an additional 7,325 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in Nuvation Bio in the 2nd quarter worth $65,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Nuvation Bio by 20.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 36,486 shares of the company’s stock valued at $71,000 after acquiring an additional 6,307 shares during the period. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 29.93% of the stock is currently owned by company insiders.

Nuvation Bio Stock Performance

Shares of NYSE:NUVB opened at $5.17 on Tuesday. The firm has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $2.75. Nuvation Bio Inc. has a 52 week low of $1.54 and a 52 week high of $5.55. The company has a quick ratio of 9.38, a current ratio of 9.39 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.77 billion, a P/E ratio of -8.21 and a beta of 1.48.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%. On average, analysts expect that Nuvation Bio Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NUVB. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Nuvation Bio in a report on Monday, October 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Nuvation Bio in a research report on Friday, September 19th. Wall Street Zen raised shares of Nuvation Bio from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Royal Bank Of Canada upped their target price on shares of Nuvation Bio from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.86.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.